TGFB1 and Hepatic fibrosis: The treatment has been found to significantly inhibit the TGF-β/Smad signaling pathway, which effectively suppresses HSC activation. This leads to an improvement in angiogenesis and a subsequent alleviation of hepatic fibrosis.